Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1984 1
1985 2
1986 5
1987 2
1988 4
1989 4
1990 3
1991 1
1992 1
1993 7
1994 1
1995 5
1996 4
1997 1
2000 2
2001 3
2004 1
2005 3
2006 4
2007 4
2008 6
2009 2
2011 6
2012 6
2013 5
2014 5
2015 4
2016 5
2017 4
2018 8
2019 7
2020 5
2021 2
2022 1
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Results by year

Filters applied: . Clear all
Page 1
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Partridge AH, et al. N Engl J Med. 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. N Engl J Med. 2023. PMID: 37133584 Free PMC article. Clinical Trial.
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Francis PA, et al. N Engl J Med. 2018 Jul 12;379(2):122-137. doi: 10.1056/NEJMoa1803164. Epub 2018 Jun 4. N Engl J Med. 2018. PMID: 29863451 Free PMC article. Clinical Trial.
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab.
Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE. Filho OM, et al. Among authors: dell orto p. Cancer Discov. 2021 Oct;11(10):2474-2487. doi: 10.1158/2159-8290.CD-20-1557. Epub 2021 May 3. Cancer Discov. 2021. PMID: 33941592 Free PMC article. Clinical Trial.
Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial.
Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A; International Breast Cancer Study Group Trial 23-01. Galimberti V, et al. Lancet Oncol. 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5. Lancet Oncol. 2018. PMID: 30196031 Clinical Trial.
[Cavernosography].
Patelli E, Mantovani F, Taverna GL, Dell'Orto P. Patelli E, et al. Among authors: dell orto p. Arch Ital Urol Androl. 1994 Sep;66(4):183-6. Arch Ital Urol Androl. 1994. PMID: 7951355 Italian.
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen SJ, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown LC, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller B, Jochum W, Bonnefoi H, Martino S, Davidson NE, Geyer C, Chia SK, Ingle JN, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates AS, Goldhirsch A, Fleming GF, Francis PA, Speed TP, Regan MM, Loi S. Luen SJ, et al. Among authors: dell orto p. Ann Oncol. 2023 Apr;34(4):397-409. doi: 10.1016/j.annonc.2023.01.009. Epub 2023 Jan 25. Ann Oncol. 2023. PMID: 36709040 Free PMC article.
PSA mass screening: is there enough evidence?
Rocco B, Grasso A, Sosnowski R, Dell'orto PG, Albo G, Castle E, Coelho R, Patel V, Mottrie A. Rocco B, et al. Among authors: dell orto pg. Cent European J Urol. 2012;65(1):4-6. doi: 10.5173/ceju.2012.01.art1. Epub 2012 Mar 19. Cent European J Urol. 2012. PMID: 24578912 Free PMC article. Review.
Robotic prostatectomy: an update on functional and oncologic outcomes.
Cozzi G, Lorenzis ED, Palumbo C, Acquati P, Albo G, Dell'orto P, Grasso A, Rocco B. Cozzi G, et al. Among authors: dell orto p. Ecancermedicalscience. 2013 Sep 26;7:355. doi: 10.3332/ecancer.2013.355. Ecancermedicalscience. 2013. PMID: 24101944 Free PMC article. Review.
New robotic systems: first head-to-head comparison between Hugo RAS and Versius CMR in the pre-clinical setting.
Sighinolfi MC, Rocco B, Terzoni S, Morandi A, Afonina M, Assumma S, Calcagnile T, Turri F, Sangalli M, Panio E, Sarchi L, Grasso A, Dell'orto P, Pozzi E, Ramondo A, Santangelo E, Petix M, Gaia G. Sighinolfi MC, et al. Among authors: dell orto p. Minerva Urol Nephrol. 2024 Feb;76(1):1-4. doi: 10.23736/S2724-6051.23.05568-4. Minerva Urol Nephrol. 2024. PMID: 38426418 Free article. No abstract available.
127 results